Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Priority Review Vouchers: Buyers Beware!

Oct 14 2015

• By Michael McCaughan

Related Content

PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen

Sep 04 2014

Gilead Puts High Premium On Priority Review Voucher; Deal May Help Protect Lead In HCV

Dec 03 2014

Treat and Trade: The New Priority Review Voucher Market

Jul 01 2008

Related Companies

AbbVie Inc.

United Therapeutics Corporation

BioMarin Pharmaceutical Inc.

Sanofi

Gilead Sciences, Inc.

Travere Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

Novartis AG

Wellstat Therapeutics Corporation

AstraZeneca PLC

Bayer AG

Roche Holding AG

Eisai Co., Ltd.

Shionogi & Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

AstraZeneca PLC

Merck & Co., Inc.

GSK plc

Santhera Pharmaceuticals

Sarepta Therapeutics, Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window